Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults

This study has been completed.
Sponsor:
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Information provided by (Responsible Party):
Norman Ilowite, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
ClinicalTrials.gov Identifier:
NCT00534495
First received: September 24, 2007
Last updated: September 15, 2014
Last verified: September 2014
History of Changes
  Purpose

Systemic juvenile idiopathic arthritis (SJIA) is a type of arthritis that typically occurs before 16 years of age. SJIA usually involves heat, pain, swelling, and stiffness in the body's joints. It can also involve fever, rash, anemia, and inflammation in various parts of the body. Rilonacept is a drug that can reduce inflammation. The purpose of this study is to determine whether a rilonacept drug regimen initiated early is more effective than a similar rilonacept drug regimen initiated 4 weeks later when treating children and young adults with SJIA.


Condition Intervention Phase
Juvenile Idiopathic Arthritis
 Biological: Rilonacept
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT)

Resource links provided by NLM:

Drug Information available for: Rilonacept
U.S. FDA Resources

Further study details as provided by Montefiore Medical Center:

Primary Outcome Measures:
  • Time to response to treatment, as determined by a modified JIA ACR30 requiring no fever, coupled with a requirement for corticosteroid taper in participants who are taking corticosteroids [ Time Frame: At Week 12 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to response to treatment, as determined by JIA ACR50 and JIA ACR70 [ Time Frame: At Week 12 ] [ Designated as safety issue: No ]
  • Pediatric Quality of Life Inventory [ Time Frame: At Weeks 12 and 24 ] [ Designated as safety issue: No ]
  • Physical function as determined by Childhood Health Assessment Questionnaire [ Time Frame: At Weeks 12 and 24 ] [ Designated as safety issue: No ]
  • Presence of systemic features [ Time Frame: At Weeks 12 and 24 ] [ Designated as safety issue: No ]
  • Serious adverse events, infections, development of MAS [ Time Frame: At Weeks 12 and 24 ] [ Designated as safety issue: Yes ]
Enrollment: 71
Study Start Date: November 2008
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1
Loading dose of rilonacept (4.4mg/kg) at Week 0, followed by rilonacept 2.2 mg/kg/week for the remainder of the study
 Biological: Rilonacept
2.2 mg/kg subcutaneously
Other Names:
  • IL-1 Trap
  • Arcalyst
Placebo Comparator: Group 2
Placebo for 4 weeks, followed by rilonacept loading dose (4.4mg/kg), followed by rilonacept 2.2 mg/kg/week for the remainder of the study
 Biological: Rilonacept
2.2 mg/kg subcutaneously
Other Names:
  • IL-1 Trap
  • Arcalyst

Detailed Description:

The current standard treatment for SJIA includes nonsteroidal anti-inflammatory drugs (NSAIDS) and corticosteroids. However, in most people, NSAIDS do not completely control the disease. Also, no studies have been done to prove which medication or combination of medications is best to treat children and adolescents with SJIA. Interleukin-1 (IL-1), a protein secreted by certain cells in the body, assists in regulating immune and inflammatory responses. Too much IL-1 can be harmful and has been shown to play a role in the inflammation associated with a variety of diseases, including SJIA. Rilonacept is a drug that inhibits IL-1 activity. The purpose of this study is to determine whether a rilonacept drug regimen initiated early is more effective than a similar rilonacept drug regimen initiated 4 weeks later when treating children and young adults with SJIA. This study will also evaluate the safety of rilonacept, and various tissue samples will be collected from participants for future genetic studies.

This study will last 6 months. Participants will be randomly assigned to one of two groups:

  • Group 1 participants will receive rilonacept injections at a dose of 4.4mg/kg at study entry (loading dose), then 2.2 mg/kg weekly until Week 4. At Week 4, they will receive a loading dose of placebo, followed by weekly rilonacept injections at 2.2 mg/kg for the duration of the study.
  • Group 2 participants will receive placebo at study entry and then during the first 4 weeks of treatment. At Week 4, they will receive a loading dose of rilonacept injections of 4.4 mg/kg, followed by weekly rilonacept injections at a dose of 2.2 mg/kg for the duration of the study.

Participants will continue any previous corticosteroid therapy, but in tapering doses. All participants will attend study visits at Weeks 0, 2, 4, 6, 8, 10, 12, 14 and 24. Study visits will include a physical exam, joint exam, blood collection, interview, and questionnaires. Urine collection may occur for some female participants. Other evaluations may be performed by the participant's regular doctor. Throughout the study, participants will maintain at-home diaries to record fever, morning stiffness and pain, when rilonacept or placebo was taken, any side effects experienced from treatment, and any additional medications that were taken.

  Eligibility
Ages Eligible for Study:   18 Months to 19 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Fulfills International League Against Rheumatism (ILAR) criteria for SJIA
  • Duration of SJIA lasting at least 6 weeks since onset
  • Active disease as defined by at least two joints with active disease
  • Not currently receiving methotrexate OR if taking methotrexate, the dose has remained stable or has been discontinued for 4 weeks prior to screening
  • Has never received certain biologics OR if previously received biologics, discontinued etanercept for at least 4 weeks prior to screening and discontinued infliximab or adalimumab for at least 8 weeks prior to screening
  • Not currently receiving corticosteroids OR if taking oral corticosteroids, the dose has remained stable between 2 and 60 mg/day for at least 2 weeks prior to screening

Exclusion Criteria:

  • Past treatment with anakinra, rilonacept, or other biologic IL-1 inhibitor
  • Treatment with other disease-modifying antirheumatic drugs (DMARDs) including, but not limited to, azathioprine, sulfasalazine, cyclosporine, and thalidomide within 4 weeks of screening
  • Treatment with leflunomide without cholestyramine washout at the end of therapy
  • Treatment with cyclophosphamide within 3 months of study entry
  • Treatment with tacrolimus or tocilizumab within 4 weeks of study entry
  • Treatment with rituximab within 6 months of study entry
  • Treatment with intravenous immunoglobulin (IVIG) within 4 weeks of screening
  • Kidney disease
  • AST or ALT levels more than two times the upper limit of normal
  • Bilirubin levels higher than 1.5 mg/dl
  • Thrombocytopenia, leukopenia, or neutropenia
  • Abnormal prothrombin time (PT) and partial thromboplastin time (PTT) tests
  • Low levels of plasma fibrinogen
  • Evidence of chronic recurrent infection or other significant, non-SJIA illness that might interfere with study participation
  • Psychological or cognitive difficulties that might interfere with study participation
  • Current drug or alcohol abuse
  • Anticipated poor compliance to assigned study regimen
  • Participation in another clinical trial within 30 days of study entry
  • Major surgical procedure within 3 months of study entry
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00534495

Locations
United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10467
Sponsors and Collaborators
Montefiore Medical Center
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Investigators
Principal Investigator: Norman T. Ilowite, MD Montefiore Medical Center
  More Information

No publications provided

Responsible Party: Norman Ilowite, Chief, Division of Rheumatology, Children's Hospital at Montefiore, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
ClinicalTrials.gov Identifier: NCT00534495     History of Changes
Other Study ID Numbers: N01 AR070015, 268200700015C-2-0-0, HHSN2682007000015C
Study First Received: September 24, 2007
Last Updated: September 15, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Montefiore Medical Center:
Systemic Juvenile Idiopathic Arthritis
Juvenile Rheumatoid Arthritis
Systemic Juvenile Rheumatoid Arthritis

Additional relevant MeSH terms:
Arthritis
Arthritis, Juvenile
Autoimmune Diseases
Connective Tissue Diseases
 Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on February 27, 2015